Skip to main content
Caplight Logo









Modulim

Modulim

Private
Irvine, CaliforniaHealthcare & Life Scienceshttps://modulim.com/

Last Round

Grant

May 18, 2023

Total Funding Raised

$16.11M

Company Overview

Modulim is a medical device company that develops and commercializes non-invasive optical imaging platforms powered by spatial frequency domain imaging (SFDI) to assess microvascular tissue health for the prevention and management of chronic wound complications.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical Imaging, Healthcare Analytics, Health IoT

Business Model

B2B

Customer Profile

Hardware + Subscription, Government Contracts

AI Layer

Non-AI

Keywords

Spatial Frequency Domain ImagingSFDImicrovascular assessmentperfusion assessmentlimb preservationmedical imaging devicenon-invasive imagingtissue oxygenationMedTechdiabetic foot ulcer preventionwound care technologypoint-of-care diagnosticsPeripheral Arterial DiseasePADCPT code reimbursementFDA 510(k) clearanceHIPAA-compliant cloud

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Modulim Comparables

Compare Modulim with similar companies based on industry and business-model similarity.

Modulim comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MIMOSA Diagnostics
84%
VOTIS Subdermal Imaging Technologies
82%
Kent Imaging
82%

Modulim Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 18, 2023
Series CDec 8, 2020
DebtApr 27, 2020
Series BJan 23, 2019
GrantNov 17, 2017
Series A
Nov 17, 2017

Key People

Founding team and executive leadership

Amaan Mazhar

Chief Executive Officer

Executive Team

Modulim Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2023

    $3M grant from the United States Army Medical Materiel Development Activity.

  • Dec 8, 2020

    Raised Series C round

Modulim Filings

Explore SEC and related filing metadata, where available.

Modulim filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Modulim's valuation, stock price, and market status.

Is Modulim a public or private company?

Modulim is a private company.

What is the current stock price of Modulim?

Modulim is a private company with no public stock price. No recent secondary market data is available.

How much is Modulim worth (valuation)?

Valuation information for Modulim is not publicly available.

Can I buy Modulim stock?

Modulim shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Modulim's last funding round?

Modulim's most recent funding round was Grant on May 18, 2023.

Who are the main investors in Modulim?

Key investors in Modulim include National Institute of Arthritis and Musculoskeletal and Skin Diseases, Grey Sky Venture Partners, NIH RADx, Pangaea Ventures.

Will Modulim IPO soon?

No public IPO plans have been announced for Modulim.

How can I track Modulim secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Modulim's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIrvine, California
Employee Range8
Year Founded2002
Last FundingMay 18, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?